International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Economic Impact of AI-Driven Precision Medicine (Studying the Economic Implications of AI-Powered Precision Medicine Approaches, Including How Personalized Treatments Can Influence Healthcare Spending, Patient Outcomes, and Overall System Efficiency)

Sulagna Dhal[1], Anshul Khairari[2], Anto LXRA Selvarathinam[3], Priyabrata Thatoi[4], Sushree Swapnil Rout[5]

[1]Arizona State University, Tempe, Arizona, 85287
[2]University of Texas, Dallas, Texas, 75080
[3]Grand Valley State University, Michigan, USA, 49534
[4]Oklahoma State University, Stillwater, Oklahoma, 74078
[5]Dr.L.H. Hiranandani Hospital, Mumbai, India, 40076

ABSTRACT:
AI in precision medicine is considering a major turning point in health care toward personalized treatments per each one's profile, hence playing an important role in patient outcomes while affecting the bottom line in healthcare. This paper examines the economic implications of AI- driven precision medicine, including how the use of AI tools-such as machine learning and predictive analytics-will add to developing treatments tailored to a particular patient's genetics, medical history, and current health data. The study presented underlined economies that could be obtained by avoiding superfluous treatments, reduction in hospital readmission rates, and adverse drug reactions by analyzing the tendencies in healthcare spending. Further, AI enhances the overall efficiency of the health system through speeding up drug development, smoothing clinical processes, and raising the quality of decision-making on patient care. Notwithstanding the brilliant prospects, general acceptance of AI in healthcare systems might be prospective due to high implementation costs, data privacy concerns, and regulatory hurdles. Done differently, AI-driven precision medicine can significantly enhance patient care while lowering long-term healthcare costs. But complete global realization of this dream requires resolution of ethical, financial, and operational challenges.

Keywords: AI-driven precision medicine, personalized treatment, healthcare economics, AI in healthcare, healthcare expenditure, improvement of patient outcomes, efficiency in the systems, economic consequences of

INTRODUCTION:

AI has brought about a gradual upward change in many sectors, and one of the most promising usages of AI is precision medicine [1] [2]. Precision medicine has become the vanguard of innovation in health care, catering especially to the patient's characteristics. With the prowess of AI, precision medicine analyzes an immense number of datasets and generates treatment programs for each particular need, hence predicting patient outcomes with unparalleled accuracy. The development carries immense implications, not only in the realm of patient care but also in terms of health economic ecosystems worldwide. Artificial Intelligence-driven precision medicine [3],[4] is likely to reformulate healthcare spending, patient outcomes, and overall system efficiencies in previously unthought-of ways.

The economic effect of AI precision medicine does not stop at the direct investment costs in these technologies. As much as there is a very big initial investment in the infrastructure and tools required for AI, long-term savings and efficiencies are also believed to compensate for that cost. AI can save health care spending by reducing the try-and-error approach towards treatments, less readmission in hospitals, and efficient use of the resources. Also, the treatment plans worked out in personalized ways through AI bring about better patient outcomes, which in turn reduces financial burdens on patients and healthcare providers. These improvements do have ramifications for expecting a shift toward more sustainability and efficiency in the healthcare system. Table 1 shows the economic impact of AI-driven precision medicine below:

Table 1. Economic Impact of AI-Driven Precision Medicine

Economic Indicator	Current Healthcare Approach	AI-Driven Precision Medicine
Healthcare Spending (per capita)	$11,000 (USA, 2023)	Projected reduction 10-20%
Hospital Readmission Rate	15-20%	Potential reduction 25-30%
Cost of Adverse Drug Reactions (annually)	$30 billion (USA, 2023)	Estimated reduction 30-40%
Treatment Success Rate	50-60%	Increased to 70-80%
Patient Outcome Improvement (Quality of Life Score)	60-70%	80-90% improvement

Apart from increased accessibility, another critical driver of the economic implications involves patient outcomes. AI can notably raise the quality of care that patients receive, thus enabling more accurate diagnoses and treatments. Improved patient outcomes, in a dual benefit, not only ensure that patients benefit through more effective treatments, but they also contribute to the economic efficiency of health care systems. Proper and timely treatment relieves the patients from complications; then, the hospital stays are shorter, thus reducing further interventions. Lesser use of health resources automatically requires lesser costs on the part of health care providers and the patients.

Besides cost savings, AI-driven precision medicine can help improve the efficiency in the overall system: AI automates routine tasks such as data analysis and patient monitoring [5], [6] so healthcare workers can devote time to more complex, value-added activities. This shift may involve increased productivity and better use of human resources by the healthcare system. More significantly, AI facilitates better decision-

making [7] since it offers real-time insights and recommendations to the healthcare professionals; these are resultant in making a more appropriate and timely intervention. This means health systems work more easily and effectively, therefore being enabled to enhance their patient care.

However, with regard to AI-powered precision medicine, there is much economic perspective to tackle the challenge. Application of AI in health [8], [9] requires huge investments in both technology and training, as well as the development and strengthening of regulatory frameworks that would ensure the safe and responsible application of AI. Besides, it is concerned that it may further result in inequalities in access to healthcare and health outcomes. With the increased momentum in the adoption of precision medicine, the time to address such challenges is a matter of equity in benefit sharing arising from AI-driven healthcare. Despite these hurdles, the economic benefits that may emanate from AI-driven precision medicine could be substantial. In the context of the increasing pressures on healthcare systems worldwide in terms of ballooning costs and rising demand for care, AI represents an exciting opportunity to create efficiencies that will result in better patient outcomes without added costs. Specifically, healthcare providers can deploy AI to enable more personalized, effective, and efficient care, and thus alter the economics of health care.

Conclusively, the economic consequences of AI precision medicine run along several lines, one being a possible huge impact on the structure of healthcare spending, patient outcomes, and efficiency in general, while the initial costs linked to the adoption of these AI technologies are abnormally high; long-term benefits will presumably be worth more. This is AI that will continue to evolve and be increasingly embedded in healthcare; economic implications will likely only grow with time, finally leading toward a new era of personalized medicine and healthcare innovation.

This article answers the following questions:

RQ1: How does the application of AI-driven precision medicine impact economic healthcare spending in general, and what savings are possible from that?

RQ2: What are the most influential factors that define the economic efficiency of personalized treatments empowered with AI against the traditional approaches of healthcare?

RQ3: The influence of AI-driven precision medicine approaches on the treatment outcomes of patients: the treatment success rate and the quality of life.

RQ4: What is the role of AI in resource optimization and reducing the rate of readmission within a hospital of a healthcare system?

RQ5: What are the initial costs and investments needed to integrate AI-driven precision medicine into existing healthcare infrastructure?

RQ6: What are the economic implementation ethical and regulatory challenges for AI in precision medicine, and how are those issues addressed?

Topology of Review

Section 2 describes the methodology adopted for the review on the economic effect of AI precision medicine. Section 3 describes the role of AI in precision medicine by focusing on how AI algorithms and data-driven insights contribute to the personalized approaches of health care. Section 4 discusses healthcare spending, patient outcomes, and efficiency of the system as the economic implications. Section 5 discusses personalized therapeutic strategies in light of patient-centered treatment, cost-effectiveness, and complication avoidance. Section 6 goes further to highlight system-wide efficacy in optimized resources, reduced hospital readmissions, and enhanced workflow. Section 7 discusses challenges and

considerations with regard to initial cost, ethical and regulatory considerations, and equity of access to AI-powered treatments. Section 8 discusses the future directions and concludes the review by summarizing key messages and implications for integration into healthcare. Figure 1 represents the pictorial representation of the review structure.

Figure 1. Organization of the review

LITERATURE REVIEW

Hussain et al. presented a study that showcased machine learning algorithms' effectiveness in predicting adverse neurological and cardiac events in patients with relevant conditions, using logistic regression, random forest, and deep learning neural networks to create accurate models. Key risk factors identified included advanced age, male gender, comorbidities like hypertension and diabetes, and certain medications. These models exhibited high accuracy in identifying at-risk patients, highlighting potential for personalized treatment and risk stratification in clinical practice. Limitations included retrospective design and reliance on electronic health records, indicating the necessity for future research in larger, prospective cohorts [10].

Khan et al. suggested machine learning algorithms have revolutionized imaging for accurate lesion identification in medical images, aiding in early cancer detection. AI predictive models help identify patients needing intensive monitoring and customized treatment plans, improving outcomes. AI analysis of clinical factors and molecular markers enhances survival predictions, while providing personalized information for patient engagement. Ethical use of patient data for AI training, emphasizing informed consent, is crucial for advancing cancer treatment and healthcare practices [11].

Chibugo Udegbe et al. proposed that AI is transforming personalized medicine by improving patient outcomes through advanced data analysis. Deep learning algorithms have proven accurate in diagnosing conditions like cancer by analyzing medical images better than humans. AI helps create individualized

treatment plans by integrating genetic profiles and medical histories, especially beneficial in oncology for suggesting effective chemotherapy with fewer side effects. This integration expands access to high-quality healthcare, addressing regulatory hurdles for safe and effective AI use in healthcare. Interdisciplinary collaboration and ethical considerations are crucial for responsible AI integration [12]. Naik et al. highlighted AI and ML's role in advancing precision medicine, leveraging data for faster drug development and regulatory processes. Submissions to the FDA have surged from under 4 annually before 2019 to over 170 in 2022. Trustworthiness and privacy issues are key concerns, urging collaboration and data sharing among stakeholders to enhance AI's impact in healthcare. Despite challenges, AI and ML show great potential for transformative impact in precision medicine [13].

Carini et al. proposed the use of artificial intelligence in drug development, with the newest application of GPT-4, in modifying drugs like dasatinib into their related compounds by facilitating custom synthesis. It can also be used to design valid chemical structures and identify target molecules in databases that could be useful in drug design. Whereas this may be the case, most AI algorithms applied in research are not practical in the clinical setting; therefore, further development and validation of those algorithms are required. The paper describes the changing regulatory environment with the presentation of draft EU regulations that call for the safety and ethics of AI in health. Ethical considerations, health equity, and stakeholder engagement are paramount for the successful integration of AI in precision medicine, enabling offsetting of disease burden and costs. Data quality, privacy, and biases in algorithms are challenges to be overcome to maximize the full benefit of AI in clinical practice [14].

Abbaoui et al. presented that precision medicine is tailored treatment, considering particular individual elements like the genetics, lifestyle, and environment of a patient. In this respect, the approach of precision medicine can definitely help in the diagnosis and treatment of stroke in a more effective way because the possibility of bringing on side effects decreases. The research paper underlines the following role of AI in stroke precision medicine. AI technologies also represent subcategories such as machine learning that will further develop the correct diagnoses and treatments. Imaging and genetic advances deepen our understanding of strokes and open ways for personalized treatment options. Success with precision medicine in stroke care will be multidisciplined in nature. Future research should aim to integrate patient-reported outcomes into AI-driven treatment plans and preference-based considerations by the patients themselves for better outcomes [15].

METHODOLOGY:

The steps we adapted to perform this review are as follows:

A. Collection of Articles

A scoping review of AI-driven precision medicine and its economic implications was performed in light of health care expenditure, patient outcomes, and efficiency in the system, following conventional protocols. The search included all peer-reviewed publications up to September 2024 and excluded short papers, reports, editorials, posters, and dissertations. The PRISMA guidelines were followed. The keywords used during the literature search included AI-driven precision medicine, personalized treatment, health economics, cost-effectiveness, patient outcomes, spending in healthcare, and system efficiency. Searches have been conducted in main databases like PubMed, Web of Science, IEEE Xplore, Google Scholar, Elsevier, and MDPI. From these, 1,200 relevant peer- reviewed articles were retrieved after an exhaustive search. The inclusion criterion was limited to those papers that, upon critical review and

analysis, directly related to the economic implications of AI in precision medicine regarding personalized treatments and efficiency within systems.

B. Search Strategy

Various inclusion and exclusion criteria had to be developed to ensure relevance in the quality of the literature selected. First, our review involved the process of title screening, abstracts, and then full texts. Included in the review was:

- Research into the economic impact of AI-powered precision medicine focused on personalized treatment approaches, system efficiency, and health outcomes.
- These studies were those that presented quantitative and qualitative metrics related both to health care spending and cost savings, improving patient outcomes.
- Papers that discussed challenges and opportunities in the integration of AI technologies within healthcare systems, particularly about cost-effectiveness and system-wide improvements.
- Original articles and conference papers were included that were peer-reviewed and provided evidence-based insights into AI's role in healthcare economics.

The Methodology of Economic Impact of AI-Driven Precision Medicine is depicted in Figure 2.



Figure 2. Methodology of Economic Impact of AI-Driven Precision Medicine

RESEARCH FINDINGS:

The results of the research in this review are presented below:

A. AI in Precision Medicine

AI in precision medicine is becoming a transformative force that changes the health provided through advanced algorithms and data analytics. This section delineates the foundational aspects of AI-driven precision medicine, discussing core AI algorithms and tools in use and providing data-driven insights to enable personalized care.

a) AI Algorithms and Tools

AI lies at the very core of precision medicine, as it considers and analyzes volumes of data in healthcare to identify patterns, predict outcomes, and suggest personalized treatment plans. A few of the most applied AI software and algorithms include the following:

- **Machine Learning:**

Machine learning algorithms, such as decision trees [16], [17], support vector machines [18], [19], and ensemble methods, are quite frequently applied to the analysis of clinical data to forecast the responses of patients to the treatments and identify risk factors for a wide range of diseases.

- **Deep Learning:**

Different models of DL, particularly those neural networks comprising CNNs [20], [21] and RNNs [22], [23] find their wide applications in medical imagining, genomics, and drug discovery. These algorithms are incredibly effective while dealing with unstructured data such as medical images, pathology slides, and genomic sequences in order to find complicated patterns.

- **Natural Language Processing (NLP):**

NLP helps in eliciting meaningful insights from unstructured clinical notes [24], [25], EHRs, and research papers with respect to treatment protocols relevant to a particular case or specific patient factors.

- **Reinforcement Learning:**

The models in reinforcement learning [26], [27] are applied to the optimization of treatment in balancing various paths of treatment through the feedback of patients in time and patient outcomes, making it personalized and dynamic healthcare.

b) Data-Driven Insights

If individual patient treatment is to be done, precision medicine is utterly dependent on data. AI provides the healthcare professional an ability to extract actionable insights from complex, heterogeneous data sets for more accurate diagnoses, personalized treatment strategies, and better patient outcomes. Key sources of data-driven insights include:

- **Genomic Data:**

AI algorithms will parse the genomic information to identify those genetic mutations [28], [29] and markers known to trigger certain diseases. Such information will be very important in developing therapies targeting those points, especially in oncology.

- **Medical Imaging:**

AI systems interpret medical images like Xrays, MRI, and CT scans [30], [31] to help in early and more accurate diagnoses of diseases. These tools help in detecting anomalies and suggest a course of treatment intervention based on analysis through the images.

- **EHRs:**

AI processing of EHRs [32] provides insight into patient histories, treatment outcomes, and population

health trends, enabling the clinicians to make appropriate decisions with respect to personalized treatments, the course of disease, and general healthcare provision.

- **Clinical Trials and Real-World Data:**

While being able to accelerate the analysis of clinical trial data and real-world evidence, AI can help answer questions regarding which treatments will most benefit certain subgroups within the population being studied. This helps enable the evolution of data-driven precision medicine. The visual representation of AI in precision medicine is shown in Figure 3.



Figure 3. AI in Precision Medicine

B. Economic Implications

The economic consequences of AI-driven precision medicine are multifaceted, touching on different dimensions of health care systems. This section discusses the most salient themes of how AI technologies and personalized treatments can affect spending, patient outcomes, and system efficiency in health care.

a) Healthcare Spending

AI-powered precision medicine can save billions of dollars for health providers by enabling better diagnosis and treatment personalization, with the possibility of early diagnosis of a disease. Such personalized treatment reduces unnecessary and burdensome trial-and-error treatments. AI systems will be able to optimize resource utilization by predicting the needs of each individual patient in advance and preventing admissions or other medical interventions. Although the initial investments in AI technologies

and infrastructures may be high, the longitudinal benefits derived through a reduction in the number of readmissions and a reduced length of stay may offset the overall costs. This section discusses striking a balance between up-front AI implementation costs and long-term economic benefits.

b) Patient Outcomes

One of the most influencing factors on the economic effect of AI in precision medicine involves how it affects value creation in improving patient outcomes. AI-designed personalized treatment plans can develop higher accuracy in medical interventions, thus leading to superior health outcomes. AI-driven systems can analyze patient data from genetic, environmental, and lifestyle factors, predict diseases, and stage appropriate interventions that enhance recovery rates. Improvement in patient outcomes could well translate into economic savings, as reducing the burden of chronic diseases minimizes complications and can often lead to faster recoveries that might lighten the long-term cost of care.

c) System Efficiency

AI-driven precision medicine holds great promise for holistic value creation in integrated healthcare systems through smoothing workflow processes, easing burdens on administration, and optimizing the use of medical resources. AI algorithms [33] help doctors make more informed decisions by ensuring speedier diagnoses and treatment planning. By automating various processes, including scheduling, billing, and patient monitoring, human intervention is limited to only mundane routine tasks, freeing up time and resources for critical care. Moreover, with the integration of AI into health systems, it enables real-time data analysis. This promotes coordination and management of care across different sectors, ensuring improvement in efficiency at the system level and reducing operational costs.

C. Personalized Treatment Approaches

AI-driven precision medicine is all about providing personalized, tailored treatment approaches that might have better results in terms of patient outcomes and cost savings, with a reduction in complications. This section deals with some economic aspects of the advantages of personalized treatments.

a) Tailored Patient Care

AI-driven precision medicine can enable health providers to propose treatments based on distinctive genetic, clinical, and lifestyle knowledge of a patient. With the large amounts of data and patterns, the AI system is in a position to suggest the most appropriate treatments according to each one of them rather than the "one-size-fits-all" approach. The result is minimal unnecessary treatment, reduced trial-and-error in the selection of medication [34], [35], and shorter recovery times. The economic benefit lies in the reduction of wasted resources and optimization of care delivery, leading to more efficient healthcare spending.

b) Cost-Effectiveness

Probably the main economic benefit of AI-powered personalized medicine will stem from the fact that, in some respect, it could be cost-effective. Though initial implementations of AI systems and genomic testing are really very expensive, potential long-term savings may be realized through better-informed and more precise treatment decisions. This treatment may avoid expensive readmissions to hospitals, unnecessary procedures, and long-term uses of ineffective drugs. Besides improving treatment accuracy, AI will contribute to lowering the overall cost of healthcare and developing effective resource allocation for financial sustainability in healthcare systems.

c) Reduced Complications

In this case, AI-driven treatment plans will have very few chances of developing treatment-related compl-

ications. Because of their potential to make exact predictions about the response a patient may have with respect to any particular medication or surgical intervention, AI algorithms will help avoid adverse reactions to certain drugs or negate unnecessary invasive procedures. Fewer complications mean fewer emergency visits, shorter hospital stays, and follow-up treatments-which has an economic positive impact. This reduction in complications improves the patient's outcomes and adds to the system's financial health by minimizing long-term healthcare expenses.

D. System-Wide Efficiency

The introduction of AI-driven precision medicine impacts patient care; it clearly will contribute much to the general efficiency of health care systems. The following section sets out how AI technologies can offer system-wide improvements by optimizing resources, reducing hospital readmissions, and enhancing workflows.

a) Resource Optimization

AI-driven precision medicine allows for better utilization of resources in determining the proper courses and offerings of treatments that best serve the patient. In predicting analytics personalized to each treatment plan, many tests for unnecessary diagnoses and ineffective treatments could be prevented. Therefore, hospital resources such as staff, medical equipment, and financial wherewithal are used much more appropriately. With AI tools, it should be able to predict patient needs so that precise scheduling can be done for better utilization of healthcare infrastructure.

b) Reduction in Readmissions

AI technologies can analyze patient data to forecast complications and high-risk cases, thus supporting the prevention of hospital readmissions. By availing AI-driven insights to inform personalized care plans [36], [37], health professionals are better equipped to closely monitor patients after discharge and thus intervene early when required. This proactive approach helps not only in improving the outcomes of patients but also in reducing the financial burden on healthcare systems by cutting down costs associated with frequent readmissions.

c) Enhanced Workflow

AI-enabled systems smooth the workflow in hospitals through automating administrative and clinical processes, thereby increasing efficiency in the delivery of patient care. In performing tasks such as scheduling, data entry, and diagnostic analysis, for instance, AI eases caregivers' administrative burden. That way, they can position themselves better to be capable of caring for their patients and responding to patient needs quicker and with higher quality. AI helps in integrating data from disparate sections, hence allowing for better communication and coordination within a healthcare system for effective management of work flow.

The summary of a literature review is shown in Table 2.

Author, Year	Target Variable	Input	Architecture	Pre-Processing	Dataset	Outcome	Output
Hussain et al.,2024	Adverse Neurological and Cardiac Events	Clinical Data, Electronic Health Records	Logistic Regression, Random, Forest,	Retrospective Study, Feature Engineering	Electronic Health Records from Multiple	Risk of Neurological and Cardiac Events	Binary Risk Classifica tion

			Deep Learning				
Khan et al., 2024	Cancer Lesion Identification	Medical Images, Clinical Data, Molecular	AI Predictive Models, Neural Networks	Image Segmentation, Feature	Imaging Datasets from Various Cancer Studies	Lesion Identification and Monitoring	Binary and Multi-class Lesion Detection
Chibuogo Udegbe et al., 2024	Cancer Diagnosis and Treatment	Genetic Profiles, Medical Images, Patient Histories	Deep Learning	Data Integration of Genetic and Medical Histories	Oncology Dataset with Genetic and Imaging Data	Personalized Chemotherapy Treatment	Multi-class Prediction for Treatment
Naik et al., 2024	Drug Development and Regulation Regulation	Clinical Trial Data, Drug Development Data	Machine Learning, FDA Submission Data	Preprocessing of Regulatory and Clinical Data	FDA Regulatory Data and Clinical Trials	Drug Development Speed and Efficacy	Binary Classifica tion
Carini et al., 2024	Drug Synthesis and Target Identificatio n	Chemical Compounds, Drug Data	GPT-4 Assisted Drug Design	Chemical Structure Analysis	Chemical Structure Databases,Drug Target Databases	Drug Modifications and Synthesis	
Abbaoui et al., 2024	Stroke Precision Medicine	Imaging Data, Genetic Profiles, Patient Data	Machine Learning, AI Techniques	Genetic Data Integration, Imaging Analysis	Stroke Imaging Data and Genetic Information	Stroke Diagnosis and Treatment	

Challenges:

Artificial Intelligence-driven precision medicine holds much promise in improving health outcomes and efficiencies. Yet, not to be minimized are the challenges and considerations that must be foregrounded regarding AI-driven precision medicine [38], [39]. Three of the crucial issues that will be discussed in this work are initial costs and investment; ethical and regulatory concerns; and equity in access.

a) Initial Costs and Investments

It starts with large upfront investments in technology, infrastructure, and training. Every healthcare practitioner will have to invest in high-performance computing systems, data storage, and AI software-which is not a trivial investment-and then there's the cost of training healthcare professionals to make use of AI-driven tools and interpret AI-generated insights. These initial costs may be prohibitively expensive

for many healthcare systems, especially those with limited resources. In addition, ongoing maintenance and updates, at times requiring technical support, are additional financial burdens in the longer run. Although AI in precision medicine may eventually bring about long-term savings by driving efficiency and improving patient outcomes, this high initial investment remains one of the critical impediments to wide implementation.

c) Ethical and Regulatory Concerns

AI-driven precision medicine has much to consider regarding ethical and regulatory issues in terms of making such technologies applied safely and responsibly. The main key ethical issues are the protection of a patient's privacy and sensitive health data. AI systems, being data-driven, are expected to handle huge volumes of data, including personal health information that should be kept secure to avoid eventual data breaches and misuse. Besides this, there are also accountability issues in regard to AI in clinical decision-making: who takes the blame in the event of a bad patient outcome from an AI-generated recommendation? Also, clarity is needed on the regulatory framework that applies to the development, testing, and deployment of AI tools in health. This requires guidelines from regulatory agencies to ensure that such AI systems have been subjected to extensive testing for safety, effectiveness, and fairness before embedding them into clinical practice. But without vigorous ethical and regulatory oversight, the potential for harm, bias, and misuse of AI-driven precision medicine is still very great [40].

d) Equity in Access

Equitable access to these advanced technologies remains one of the most serious challenges facing AI-driven precision medicine. Generally, AI tools tend to be developed and deployed within high-resource settings-a phenomenon that hugely raises the stakes in terms of equity implications because not all populations of patients are represented in those developments. Socioeconomic disparities, geographic barriers, and inadequacies in healthcare infrastructures potentially limit the populations of some patient groups from benefiting from AI-powered treatments. Moreover, biases in the data used for training AI models lead to unequal outcomes in that AI systems may not work that well for minority or otherwise disadvantaged populations. Addressing equity in access means making deliberate efforts toward ensuring AI-driven precision medicine is affordable, available, and effective for all groups of patients regardless of their background or location. This will perhaps mean policy interventions, investing specifically in areas of the most significant needs, and developing more inclusive models of AI that are diverse on the population level.

Future Directions:

The future for AI-driven precision medicine is brilliant and holds enormous potential for even further transformation in healthcare. As these AI technologies continue to advance, more sophisticated machine learning models will integrate into advanced data analytics, yielding better precision in medical treatments. The role of AI in the future should, therefore, be extended to various medical conditions. In this direction, equal opportunity for AI-driven treatments must be given. Ethical and privacy concerns on the sharing and usage of patient data have to be considered. Various healthcare provider inputs, AI researchers, and policy experts will thus help shape regulatory frameworks which balance innovation with safety. Demonstrating long-term value by studying real-world economic outcomes of AI in health systems, such as cost savings and optimization of healthcare resources, will be essential. Global adoption and a reduction in healthcare disparities will also require further investment in AI infrastructure, particularly in low- resource settings.

Conclusion:

It can basically change the face of healthcare in regards to its economic impact, among other ways. For instance, AI can help better patient outcomes, efficient use of resources, and also the overall management of healthcare systems with personalized treatment methods. It was seen from this review that AI-powered precision medicine is able to generate substantial cost savings with a reduction in a number of treatments, hospitalizations, and diagnostic errors. Thus, personalized care can enhance patient satisfaction and improve long-term health outcomes. This would eventually reduce the financial burden on the healthcare providers as well as the patients. However,

AI adoption in precision medicine also has its own challenges, including high initial costs, regulatory barriers, and data privacy and security. Such barriers must be overcome for the full realization of economic benefits from AI applications in healthcare. Large-scale studies and actual implementations are necessary to determine such long-term economic impacts and effectiveness of such AI-driven interventions. While AI-powered precision medicine is envisioned to raise the quality and cost-effectiveness of healthcare, successful deployment depends on whether the current limitations could be surmounted and the place of AI technologies in the existing framework of healthcare. Further evolution of AI will no doubt continue to play a critical role in shaping future health care economics-to more effective and patient-centered health systems.

References:

1. A. Lawson McLean, "Towards Precision Medicine in Spinal Surgery: Leveraging AI Technologies," 2024. doi: 10.1007/s10439-023-03315-w.
2. B. Allen, "The Promise of Explainable AI in Digital Health for Precision Medicine: A Systematic Review," 2024. doi: 10.3390/jpm14030277.
3. Y. Qiu and F. Cheng, "Artificial intelligence for drug discovery and development in Alzheimer's disease," 2024. doi: 10.1016/j.sbi.2024.102776.
4. L. Tong *et al.*, "Integrating Multi-Omics Data With EHR for Precision Medicine Using Advanced Artificial Intelligence," *IEEE Rev Biomed Eng*, vol. 17, 2024, doi: 10.1109/RBME.2023.3324264.
5. F. Mughal, A. Wahid, and M. A. K. Khattak, "Artificial Intelligence: Evolution, Benefits, and Challenges," in *Internet of Things*, 2022. doi: 10.1007/978-3-030-92054-8_4.
6. O. Khan, M. Parvez, P. Kumari, S. Parvez, and S. Ahmad, "The future of pharmacy: How AI is revolutionizing the industry," *Intelligent Pharmacy*, vol. 1, no. 1, 2023, doi:10.1016/j.ipha.2023.04.008.
7. V. Tucci, J. Saary, and T. E. Doyle, "Factors influencing trust in medical artificial intelligence for healthcare professionals: a narrative review," 2022. doi: 10.21037/jmai-21-25.
8. S. Reddy, S. Allan, S. Coghlan, and P. Cooper, "A governance model for the application of AI in health care," 2020. doi: 10.1093/jamia/ocz192.
9. J. Qiu *et al.*, "Large AI Models in Health Informatics: Applications, Challenges, and the Future,"*IEEE J Biomed Health Inform*, vol. 27, no. 12, 2023, doi: 10.1109/JBHI.2023.3316750.
10. I. Hussain, S. Khan, and M. Bin Nazir, "Precision Medicine: AI and Machine Learning Advancements in Neurological and Cardiac Health."
11. M. Khan, A. Shiwlani, M. U. Qayyum, A. Mannan, K. Sherani, and H. K. Hussain, "2 Illinois institute of technology Chicago 10 W 35th ST," vol. 60616, no. 5.
12. F. Chibugo Udegbe, O. Roseline Ebulue, C. Chukwudalu Ebulue, and C. Sylvester Ekesiobi, "AI'S IMPACT ON PERSONALIZED MEDICINE: TAILORING TREATMENTS FOR IMPROVED HEALTH OUTCOMES," *Engineering Science & Technology Journal*, vol. 5, no. 4, pp. 1386–1394, 2024, doi: 10.51594/estj/v5i4.1040.
13. K. Naik *et al.*, "Current Status and Future Directions: The Application of Artificial Intelligence/Machine Learning for Precision Medicine," Apr. 01, 2024, *John Wiley and Sons Inc*. doi: 10.1002/cpt.3152.
14. C. Carini and A. A. Seyhan, "Tribulations and future opportunities for artificial intelligence in precision medicine," Dec. 01, 2024, *BioMed Central Ltd*. doi: 10.1186/s12967-024-05067-0.

15. W. Abbaoui, S. Retal, M. Belhiah, and Y. Z. Seghroucheni, "Revolutionizing Stroke Care with AI-Powered Precision Medicine: A Narrative Review."
16. V. N. Manju, N. Aparna, and K. Krishna Sowjanya, "Decision Tree-Based Explainable AI for Diagnosis of Chronic Kidney Disease," in *Proceedings of the 5th International Conference on Inventive Research in Computing Applications, ICIRCA 2023*, 2023. doi:10.1109/ICIRCA57980.2023.10220774.
17. H. Blockeel, L. Devos, B. Frénay, G. Nanfack, and S. Nijssen, "Decision trees: from efficient prediction to responsible AI," 2023. doi: 10.3389/frai.2023.1124553.
18. Z. Ahmed, W. Degroat, H. Abdelhalim, S. Zeeshan, and D. Fine, "Deciphering genomic signatures associating human dental oral craniofacial diseases with cardiovascular diseases using machine learning approaches," 2024. doi: 10.1007/s00784-023-05406-3.
19. J. K. Solano Meza, D. Orjuela Yepes, J. Rodrigo-Ilarri, and M. E. Rodrigo-Clavero, "Comparative Analysis of the Implementation of Support Vector Machines and Long Short-Term Memory Artificial Neural Networks in Municipal Solid Waste Management Models in Megacities," *Int J Environ Res Public Health*, vol. 20, no. 5, 2023, doi: 10.3390/ijerph20054256.
20. M. Krichen, "Convolutional Neural Networks: A Survey," *Computers*, vol. 12, no. 8, 2023, doi: 10.3390/computers12080151.
21. S. Agarwal, A. S. Yadav, V. Dinesh, K. S. S. Vatsav, K. S. S. Prakash, and S. Jaiswal, "By artificial intelligence algorithms and machine learning models to diagnosis cancer," *Mater Today Proc*, vol. 80, 2023, doi: 10.1016/j.matpr.2021.07.088.
22. S. Das, R. Dey, and A. K. Nayak, "Artificial intelligence in pharmacy," 2021. doi: 10.5530/ijper.55.2.68.
23. N. Anantrasirichai and D. Bull, "Artificial intelligence in the creative industries: a review," *Artif Intell Rev*, vol. 55, no. 1, 2022, doi: 10.1007/s10462-021-10039-7.
24. D. Weissenbacher *et al.*, "Detecting goals of care conversations in clinical notes with active learning," *J Biomed Inform*, vol. 151, Mar. 2024, doi: 10.1016/j.jbi.2024.104618.
25. C. Fanconi, M. Van Buchem, and T. Hernandez-Boussard, "Natural Language Processing Methods to Identify Oncology Patients at High Risk for Acute Care with Clinical Notes."
26. Ł. Ledziński and G. Grześk, "Artificial Intelligence Technologies in Cardiology," 2023. doi: 10.3390/jcdd10050202.
27. E. Baccour, A. Erbad, A. Mohamed, M. Hamdi, and M. Guizani, "Reinforcement learning-based dynamic pruning for distributed inference via explainable AI in healthcare IoT systems," *Future Generation Computer Systems*, vol. 155, 2024, doi: 10.1016/j.future.2024.01.021.
28. A. W. Al-Humadi, K. Alabduljabbar, M. S. Alsaqaaby, H. Talaee, and C. W. le Roux, "ObesityCharacteristics Are Poor Predictors of Genetic Mutations Associated with Obesity," *J Clin Med*, vol. 12, no. 19, 2023, doi: 10.3390/jcm12196396.
29. A. Alí-Munive *et al.*, "Prevalence of genetic mutations in alpha-1 antitrypsin deficiency (aatd) in patients with chronic obstructive pulmonary disease in Colombia," *BMC Pulm Med*, vol. 23, no. 1, 2023, doi: 10.1186/s12890-023-02453-0.
30. N. G. A. (UK), "Computed tomography scan performance in people with epilepsy," *Computed tomography scan performance in people with epilepsy: Epilepsies in children, young people and adults: Evidence review B*, 2022.

31. J. Jerosch, I. Hoffstetter, and R. Reer, "Current treatment modalities of osteochondritis dissecans of the knee joint : Results of a nation-wide german survey," *Acta Orthop Belg*, vol. 62, no. 2, 1996.
32. P. Yadav, M. Steinbach, V. Kumar, and G. Simon, "Mining electronic health records (EHRs): A survey," 2018. doi: 10.1145/3127881.
33. J. Feng *et al.*, "Clinical artificial intelligence quality improvement: towards continual monitoring and updating of AI algorithms in healthcare," *NPJ Digit Med*, vol. 5, no. 1, 2022, doi:
34. 10.1038/s41746-022-00611-y.
35. A. Oliva *et al.*, "Assessing the potentiality of algorithms and artificial intelligence adoption to disrupt patient primary care with a safer and faster medication management: A systematic review protocol," 2022. doi: 10.1136/bmjopen-2021-057399.
36. G. Damiani *et al.*, "Potentiality of algorithms and artificial intelligence adoption to improvemedication management in primary care: a systematic review," *BMJ Open*, vol. 13, no. 3, 2023, doi: 10.1136/bmjopen-2022-065301.
37. I. Mikkola, M. Hagnäs, J. Hartsenko, M. Kaila, and K. Winell, "A Personalized Care Plan Is Positively Associated with Better Clinical Outcomes in the Care of Patients With Type 2 Diabetes: A Cross-Sectional Real-Life Study," *Can J Diabetes*, vol. 44, no. 2, 2020, doi: 10.1016/j.jcjd.2019.05.003.
38. I. Mikkola *et al.*, "Association of personalised care plans with monitoring and control of clinical outcomes, prescription of medication and utilisation of primary care services in patients withtype 2 diabetes: an observational real-world study," *Scand J Prim Health Care*, vol. 40, no. 1, 2022, doi: 10.1080/02813432.2022.2036458.
39. R. H. Allami and M. G. Yousif, "Integrative AI-Driven Strategies for Advancing Precision Medicine in Infectious Diseases and Beyond: A Novel Multidisciplinary Approach," *MEDICAL ADVANCES ANDINNOVATIONS JOURNAL*, vol. 1, no. 2, 2023.
40. T. Obafemi-Ajayi, A. Perkins, B. Nanduri, D. C. Wunsch II, J. A. Foster, and J. Peckham, "No-boundary thinking: a viable solution to ethical data-driven AI in precision medicine," *AI and Ethics*, vol. 2, no. 4, 2022, doi: 10.1007/s43681-021-00118-4.
41. V. Upadrista, S. Nazir, and H. Tianfield, "Secure data sharing with blockchain for remote health monitoring applications: a review," 2023. doi: 10.1007/s40860-023-0020